2023
Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014
Sankar A, Everhart A, Jena A, Jeffery M, Ross J, Shah N, Karaca-Mandic P. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014. The Joint Commission Journal On Quality And Patient Safety 2023, 49: 458-466. PMID: 37380503, DOI: 10.1016/j.jcjq.2023.05.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseFDA safety communicationPhysician characteristicsLabel prescribingCare physiciansTestosterone prescribingService administrative claims dataNon-primary care physiciansCertain physician characteristicsDrug Administration (FDA) safety communicationPrimary care physiciansAdministrative claims dataCase mix indexTestosterone therapyArtery diseaseTestosterone prescriptionsPrescribing levelsMean agePrescription trendsTeaching hospitalClaims dataPrescription levelsMedicare feePrescribingUS Food
2021
U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016
Wallach JD, Rhee TG, Edelman EJ, Shah ND, O’Malley S, Ross JS. U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016. Journal Of General Internal Medicine 2021, 37: 495-498. PMID: 33674920, PMCID: PMC8811103, DOI: 10.1007/s11606-021-06668-x.Peer-Reviewed Original Research
2019
Association Between Industry Payments to Physicians and Gabapentinoid Prescribing
Rhee TG, Ross JS. Association Between Industry Payments to Physicians and Gabapentinoid Prescribing. JAMA Internal Medicine 2019, 179: 1425-1428. PMID: 31282922, PMCID: PMC6618850, DOI: 10.1001/jamainternmed.2019.1082.Peer-Reviewed Original ResearchAssociation of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing
Fleischman W, Auth D, Shah ND, Agrawal S, Ross JS. Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing. JAMA Network Open 2019, 2: e191340. PMID: 30924899, PMCID: PMC6450314, DOI: 10.1001/jamanetworkopen.2019.1340.Peer-Reviewed Original ResearchConceptsMedicare Part D beneficiariesPart D beneficiariesOpioid toleranceClock opioid analgesicsMitigation strategy programAccess programOpioid prescribing trendsPercentage of prescriptionsInterrupted time series analysisREMS implementationBreakthrough painCohort studyPrescribing trendsOpioid analgesicsCancer definitionsMAIN OUTCOMECancer statusPatientsUS FoodDrug AdministrationPrescribingCancerFentanyl drugsPrescriptionMonthly decrease
2016
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. The BMJ 2016, 354: i4189. PMID: 27540015, PMCID: PMC4989280, DOI: 10.1136/bmj.i4189.Peer-Reviewed Original ResearchConceptsHospital referral regionsOral anticoagulantsReferral regionsDiabetes drugsDrug classesGreater prescribingMedicare Part D beneficiariesAdditional daysPart D beneficiariesMedicare Part D prescriptionsCross-sectional analysisSectional ecological studyMedicare Part DPart D prescriptionsManufacturers of pharmaceuticalsPrescribingAnticoagulantsPhysiciansDrugsPart DEducational materialsSectional analysisStudy limitationsConsulting feesAssociation
2013
Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis
King M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. The BMJ 2013, 346: f264. PMID: 23372175, PMCID: PMC3623604, DOI: 10.1136/bmj.f264.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsAntipsychotic AgentsCase-Control StudiesCentral Nervous System StimulantsCyclohexanolsDesvenlafaxine SuccinateDextroamphetamineDrug IndustryGift GivingHealth Care SectorHumansInterprofessional RelationsIsoxazolesMarketing of Health ServicesOrganizational PolicyPaliperidone PalmitatePractice Patterns, Physicians'Psychotropic DrugsPyrimidinesSchools, MedicalUnited StatesConceptsPsychotropic medicationsSubsequent prescribing behaviorPhysician prescribingPsychotropic classesOlder antipsychoticsPrescribing behaviorMAIN OUTCOMEMedicationsMedical schoolsPrescribingPhysiciansAntipsychoticsRestriction policiesDesvenlafaxinePaliperidoneStimulantsUS medical schoolsExposureLonger exposureAntidepressantsCohort
2012
State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning
Ross JS, Jackevicius C, Krumholz HM, Ridgeway J, Montori VM, Alexander GC, Zerzan J, Fan J, Shah ND. State Medicaid Programs Did Not Make Use Of Prior Authorization To Promote Safer Prescribing After Rosiglitazone Warning. Health Affairs 2012, 31: 188-198. PMID: 22232110, PMCID: PMC3319744, DOI: 10.1377/hlthaff.2011.1068.Peer-Reviewed Original ResearchConceptsState Medicaid programsPreferred drugDrug listPrior authorizationMedicaid programSafety warningsPrior authorization programHigh-cost drugsDiabetes medicationsPrescribing ratesEffective prescribingSafe prescribingMedicaid beneficiariesDiabetes drugsPrescribingState MedicaidHeart attackRosiglitazoneDrug availabilityDrugsAuthorization programPrescriptionMinimal changesMedicationsProviders
2011
Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing
Korenstein D, Keyhani S, Mendelson A, Ross JS. Adherence of Pharmaceutical Advertisements in Medical Journals to FDA Guidelines and Content for Safe Prescribing. PLOS ONE 2011, 6: e23336. PMID: 21858076, PMCID: PMC3157354, DOI: 10.1371/journal.pone.0023336.Peer-Reviewed Original ResearchConceptsSafe prescribingPharmaceutical advertisementsCross-sectional analysisFDA guidelinesAdherence ratesCounter medicationsMedian 2Inclusion criteriaDisease awarenessCurrent FDA guidelinesDrug AdministrationPrescribingPharmaceutical advertisingSerious riskUnique advertisementsAdherenceDrug namesPublic healthStudy limitationsEfficacy informationGuideline itemsMedical journalsGuidelinesFDARiskStudy of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial: A Narrative Account of a Gabapentin Seeding Trial
Krumholz SD, Egilman DS, Ross JS. Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial: A Narrative Account of a Gabapentin Seeding Trial. JAMA Internal Medicine 2011, 171: 1100-1107. PMID: 21709111, PMCID: PMC3319750, DOI: 10.1001/archinternmed.2011.241.Peer-Reviewed Original Research